{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:03:28Z","timestamp":1783620208684,"version":"3.55.0"},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1507\/endocrj.51.127","type":"journal-article","created":{"date-parts":[[2004,4,30]],"date-time":"2004-04-30T07:13:15Z","timestamp":1083309195000},"page":"127-132","source":"Crossref","is-referenced-by-count":13,"title":["Onset Age is Associated with Outcome of Radioiodine Therapy in Graves' Disease"],"prefix":"10.1507","volume":"51","author":[{"given":"Yasuyo","family":"YAMASHITA","sequence":"first","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"YAMANE","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"TAMURA","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"OKUBO","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuoki","family":"KOHNO","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. Hamilton JG, Lawrence JH (1942) Recent clinical developments in the therapeutic application of radio-phosphorus and radio-iodine. J Clin Invest 21: 624."},{"key":"2","unstructured":"2. Hertz S, Roberts A (1942) Application of radioactive iodine in the therapy of Graves' disease. J Clin Invest 21: 624."},{"key":"3","unstructured":"3. Allhabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC L, Franklyn JA (2000) Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042."},{"key":"4","unstructured":"4. Allhabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA (2001) Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 86: 3611-3617."},{"key":"5","unstructured":"5. Alexander EK, Larsen PR (2002) High dose <sup>131<\/sup> I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 87: 1073-1077."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yoshimoto M, Iino S, Yoshimura H, Ishikawa N, Momotani N, Hamada N, Ito K (1994) Five-year follow-up of two different <sup>131<\/sup> I treatment methods for Graves' disease. Endocrinol Jpn 70: 995-1006 (in Japanese).","DOI":"10.1507\/endocrine1927.70.9_995"},{"key":"7","unstructured":"7. Nodyke RA, Gilbert FI (1991) Optimal iodine-131 I in Graves' hyperthyroidism in Graves' disease. J Nucl Med 32: 411-416."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Watson AB, Brownline BE, Frampton CM, Turner JG, Rogers TG (1988) Outcome following standardized 185MBq dose <sup>131<\/sup>I therapy for Graves' disease. Clin Endocrinol (Oxf) 28: 487-496.","DOI":"10.1111\/j.1365-2265.1988.tb03683.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Haase A, Bahre M, Lauer I, Meller B, Riter E (2000) Radioiodine therapy in Graves' hyperthyroidism: Determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 108: 133-137.","DOI":"10.1055\/s-2000-5807"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM (2002) Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 29: 1118-1124.","DOI":"10.1007\/s00259-002-0877-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kaise K, Kaise N, Yoshida K, Fukazawa H, Mori K, Yamamoto M, Sakurada T, Saito S, Yoshinaga K (1991) Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease. Endocrinol Jpn 38: 429-433.","DOI":"10.1507\/endocrj1954.38.429"},{"key":"12","unstructured":"12. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N (1996) Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 81: 3257-3260."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nagayama Y, Izumi M, Nagataki S (1989) The management of hyperthyroism due to Graves' disease in Japan in 1988 The Japan Thyroid Association. Endocrinol Jpn 36: 299-314.","DOI":"10.1507\/endocrj1954.36.299"},{"key":"14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","year":"1991","unstructured":"14. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M (1991) Difference and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1: 129-135.","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"15","first-page":"68","volume":"58","year":"1942","unstructured":"15. Allen HC, Goodwin WE (1942) The scintillation counter as an instrument for in vivo determination of thyroid weight. Radiology 58: 68-79.","journal-title":"Radiology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-8419","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1148\/61.1.88","volume":"61","year":"1953","unstructured":"16. Goodwin WE (1953) Thyroid gland weight determination from thyroid scintigram with postmortem verification. Radiology 61: 88.","journal-title":"Radiology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-8419","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Berg G, Michanek A, Holmberg E, Nystrom E (1996) Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. J Intern Med 239: 165-171.","DOI":"10.1046\/j.1365-2796.1996.441788000.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38: 976-998.","DOI":"10.1210\/jcem-38-6-976"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A (1998) Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 83: 40-46.","DOI":"10.1210\/jc.83.1.40"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamada T, Aizawa T, Koizumi Y, Komiyama I, Ichikawa K, Hashimoto K (1994) Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. J Am Geriatric Soc 42: 513-516.","DOI":"10.1111\/j.1532-5415.1994.tb04973.x"},{"key":"21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","year":"1997","unstructured":"21. Vitti P, Rago T, Chiovato L, Pallinis S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"22","unstructured":"22. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes, Buell U (1999) Success rate of radioiodine treatment in patients with Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 84: 1229-1233."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Korosci TM (1995) Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease. South Med J 88: 831-836.","DOI":"10.1097\/00007611-199508000-00007"},{"key":"24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/thy.1995.5.243","volume":"5","year":"1995","unstructured":"24. Tuttle R, Patience T, Budd S (1995) Treatment with propylthiouracil before radioactive iodine therapy is associated with higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 5: 243-247.","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/51\/2\/51_2_127\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T23:25:05Z","timestamp":1585783505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/51\/2\/51_2_127\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.51.127","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}